Maintenance Selinexor Monotherapy Improves PFS in Advanced Endometrial Cancer

A survival benefit was observed in patients with advanced or recurrent endometrial cancer who were treated with maintenance selinexor.

Treatment with single-agent maintenance selinexor (Xpovio) yielded promising results in a population of patients with advanced or recurrent endometrial cancer, according to findings from the phase 3 SIENDO/ENGOT-EN5/GOG-3055 study (NCT03555422) that were presented at The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer.

Investigators reported a median progression-free survival (PFS) of 5.7 months (95% CI, 3.81-9.20) in the selinexor group vs 3.8 months (95% CI, 3.68-7.39) in the placebo group in the intent-to-treat population (ITT; HR, 0.705; 95% CI, 0.499-0.996; one-sided P = .024). In the selinexor and placebo groups, respectively, the PFS rate at 3 months was 72.4% vs 66.4%, 48.2% vs 40.9% at 6 months, 41.7% vs 34.1% at 9 months, and 35.3% vs 25.8% at 12 months.

When assessing PFS in patients by histologic subtype in the pre-specified exploratory analysis, patients with endometrioid carcinoma achieved a PFS of 9.2 months with selinexor and 3.8 months with placebo (HR, 0.573; 95% CI, 0.348-0.944; one-sided P = .014). Additionally, those with serous histology had a median PFS of 3.8 months and 3.7 months with each respective treatment (HR, 0.859; 95% CI, 0.481-1.533; P = .309). Additionally, in patients with wild-type p53 endometrial cancer, the median PFS was 13.7 months (95% CI, 9.20–not reached) in the selinexor arm and 3.7 months in the placebo arm (95% CI, 1.87-12.88; HR, 0.375; 95% CI, 0.210-0.670; one sided P = .0003).

“Selinexor demonstrated in the audited ITT population a 30% decrease in risk for progression and/or death compared with the placebo, but this was not significant in the non-audited population,” Ignace B. Vergote, MD, PhD, head of the Department of Obstetrics and Gynecology and Gynecologic Oncology, Catholic University of Leuven, Belgium.

Investigators enrolled patients with stage IV disease or who on their first relapse, including those with endometrioid, serous, undifferentiated, or carcinosarcoma histology. Patients needed to have at least 12 weeks of treatment with taxane and carboplatin followed by a partial response (PR) or complete response (CR). Previous surgery, radiotherapy, or hormonal therapy were allowed.

Patients were randomized 2:1 to receive either 80 mg of selinexor weekly until progressive disease (n = 174) or placebo (n = 89). The primary end point of the trial was investigator assessed PFS and key secondary end points included overall survival, PFS by blinded independent central review, and disease control rate. Pre-defined exploratory end points included histological subtype and molecular subclassification.

In the selinexor cohort, 33.3% of patients were 70 years or older and most patients had an ECOG performance status of 0 (56.9%) or 1 (40.8%). The majority of patients had endometrioid (55.2%) and serous (28.2%) histology. At the time of treatment with the combination chemotherapy regimen, most patients had recurrent disease (55.2%) and 44.8% had stage IV disease. Additionally, 59.8% had a PR and 40.2% had a CR following most recent chemotherapy.

Additionally, in the placebo cohort, 31.5% of patients were 70 years or older, all of whom had an ECOG performance status of 0 (60.7%) and 1 (39.3%). Most patients in the cohort had endometrioid (53.9%) and serous (31.5%) histology. Moreover, 51.7% of patients had recurrent disease and 48.3% had stage IV disease at the time of combination chemotherapy. After the most recent chemotherapy treatment, 55.1% of patients had a PR and 44.9% had a CR.

Notably, investigators stated that stratification factor of CR and PR was incorrect for 7 patients and was corrected before the database's lock and unblinding. The median follow-up was 10.2 months (95% CI, 8.97-13.57).

In terms of safety, the most common any grade treatment-emergent adverse effects (TEAEs) in the selinexor arm were nausea (84%), vomiting (52%), constipation (37%), and thrombocytopenia (37%) and grade 3/4 TEAEs included nausea (10%), neutropenia (9%), asthenia (6%), fatigue (6%), and thrombocytopenia (6%). For the placebo group, common any grade TEAEs included constipation (38%), nausea (34%), diarrhea (23%), and asthenia (21%) and grade 3/4 TEAEs included constipation (2%), nausea (1%), vomiting (1%), fatigue (1%), and asthenia (1%).

Moreover, in the selinexor arm, 49.7% of patients required a dose reduction, 51.5% needed a dose interruption, and 10.5% discontinued. For patients treated with placebo, 3.4% needed a dose reduction, 18.2% had a dose interruption, and 1.1% discontinued. No TEAEs led to death in either arm.

In terms of patient-reported quality of life, investigators did not observe any significant differences in global health, physical functioning, or symptoms.


Vergote I, Pérez Fidalgo A, Hamilton E, et al. SIENDO/ENGOT-EN5/GOG-3055: a randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona. Abstract 249.

Related Videos
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
Related Content